Poster Abstract Session:
41. Antimicrobial Stewardship: Adverse Drug Events
Thursday, October 8, 2015: 12:30 PM-2:00 PM
Room: Poster Hall

Learning Objectives:

-

Tracks: Adult ID, Epidemiology and Infection Control, Pediatric ID

Presentations:
125
Incidence of Acute Kidney Injury in Patients Treated with Vancomycin and Piperacillin/Tazobactam
W. Cliff Rutter, PharmD ; Jeffrey C. Talbert, PhD ; David S. Burgess, PharmD, FCCP
Posters
  • AKI poster_final.pdf (475.3 kB)
  • 126
    Acute Kidney Injury During Therapy with Vancomycin in Combination with Beta-Lactams
    Jessica Cox, PharmD ; W. Cliff Rutter, PharmD ; Craig Martin, PharmD ; Donna R. Burgess, RPh ; Dominique Zephyr, MA ; David S. Burgess, PharmD, FCCP
    128
    Acute kidney injury in patients on concomitant vancomycin and piperacillin/tazobactam: Are extended infusions to blame?
    Bhagyashri Navalkele, MD ; Shigehiko Karino, MD ; Jason Pogue, PharmD ; Nader Tashtoush, MD ; Bakht Nishan, MD ; Madiha Salim, MD ; Shantanu Solanki, MD ; Amina Pervaiz, MD ; Hamadullah Shaikh, MD ; Sunitha Koppula, MD ; Keith Kaye, MD, MPH, FIDSA, FSHEA
    129
    Risk factors for acute kidney injury in patients receiving concomitant vancomycin and piperacillin/tazobactam
    Jason Pogue, PharmD ; Shigehiko Karinko, MD ; Bhagyashri Navalkele, MD ; Nader Tashtoush, MD ; Bakht Nishan, MD ; Madiha Salim, MD ; Shantanu Solanki, MD ; Amina Pervaiz, MD ; Hamadullah Shaikh, MD ; Sunitha Koppula, MD ; Keith Kaye, MD, MPH, FIDSA, FSHEA
    132
    Comparison of IV Medication Administration Error Rates between Patients Prescribed Intermittent-Infusion vs. Extended-Infusion Piperacillin-Tazobactam
    Ethan Osborn, PharmD ; Kelli Cole, PharmD, BCPS ; Tyler Alverson, PharmD Candidate ; Cassius Hudson, PharmD Candidate ; Todd Gundrum, PharmD, BCPS
    133
    Hypokalemia and Acute Kidney Injury Leading to Drug Discontinuation Occur More Commonly among Patients Receiving Nafcillin Compared to Oxacillin
    J. Alexander Viehman, MD ; Louise-Marie Oleksiuk, PharmD, BCPS ; Kathleen Sheridan, DO ; Karin Byers, MD, MS ; Peimei He, MD ; Bonnie Falcione, PharmD, BCPS AQ-ID ; Ryan K. Shields, PharmD
    Posters
  • Nafcillin poster - FINAL.pdf (125.6 kB)
  • 134
    Overuse of Vancomycin Therapeutic Drug Monitoring: High Effort for Low Risk
    Zahra Kassamali, PharmD ; Alicia Stapleton, MD ; Julie Dang, PharmD ; Jennifer Curello, PharmD ; Meganne Kanatani, PharmD ; Brandy Bryant, MPH ; Daniel Z. Uslan, MD, MS, FIDSA
    135
    Evaluation of a Pharmacy-Driven Vancomycin Protocol and Predictors of Supratherapeutic Vancomycin Troughs
    Kati Shihadeh, PharmD ; Bryan Knepper, MPH, MSc, CIC ; Heather Young, MD ; Timothy Jenkins, MD
    Posters
  • 135_IDWPOSTER.pdf (154.4 kB)
  • 136
    A computerized order set entry (CPOE) for vancomycin dosing results in improved clinical outcomes in adult patients treated at an academic medical center
    Sandra Susanibar-Adaniya, MD ; Kevin Kuriakose, MD ; Sunita Parajuli, MD ; Krystina Walker, MD ; Jorge Jo-Kamimoto, MD ; Karam Ayoub, MD ; Marie Saylors, MPH ; Jeremy Bariola, MD
    137
    Comparison of Clinical Outcomes Between Two Meropenem Dosing Strategies in an Obese Population
    Rachel Marini, PharmD ; Christina Andrzejewski, PharmD ; Louise-Marie Oleksiuk, PharmD, BCPS ; Laura Wilson, PharmD ; Henry Freedy, PharmD
    Posters
  • IDSA 2.pdf (209.2 kB)
  • 138
    An Antimicrobial Prescription Optimization System Improves the Adequacy of Antibacterial Dosage in Obese Inpatients
    Stephanie Sirard, M.Sc. ; Vincent Nault, M.Sc. ; Marie-France Langlois, MD ; Julie Perron, B.Pharm., M.Sc. ; Louis Valiquette, MD, MSc
    Posters
  • IDWEEK S Sirard.pdf (4.7 MB)
  • 140
    One-Time Dose of Gentamicin (GENT) for Surgical Prophylaxis (SP) Does Not Increase Risk for Postoperative (POSTOP) Acute Kidney Injury (AKI)
    Zhe Han, PharmD ; Natasha Pettit, PharmD ; Amanda Dugal, PharmD ; Joseph Pariser, MD ; Blake Anderson, MD ; Shane Pearce, MD ; Gary Steinberg, MD ; Norm Smith, MD ; Jennifer Pisano, MD
    141
    Weight and Dose Dependent Toxicity of Oral Voriconazole in a Hematologic Malignancy Population
    Jeffrey Jansen, Pharm.D. ; James Lewis II, PharmD, FIDSA ; Graeme Forrest, MBBS, FIDSA
    Posters
  • Vori Poster Final Draft.pdf (194.1 kB)
  • 142
    Cefepime use and acute brain injury in critically ill patients
    John O'horo, MD, MPH ; Dereddi Raja Reddy, MD ; Tarun Singh, MBBS ; Rahul Kashyap, MBBS ; James Steckelberg, MD, FIDSA ; Ognjen Gajic, MD ; Alejandro Rabinstein, MD
    143
    Treatment Outcomes and Adverse Drug Reactions Associated with Ceftaroline Use
    Kimberly Blumenthal, M.D. ; James Kuhlen Jr., MD ; Ana Weil, MD, MPH ; Christy Varughese, PharmD ; David W. Kubiak, PharmD ; Aleena Banerji, MD ; Erica S. Shenoy, MD, PhD
    144
    Evaluation of Peripheral Eosinophilia in Patients on Daptomycin
    Guinevere Ogburn, Pharm.D. ; Niva Misra, M.D. ; Mark Rasnake, MD ; Brandon Sammons, M.D. ; Jennifer Mendez, Pharm.D. ; R. Eric Heidel, PhD
    Posters
  • Poster ID Week.pdf (368.8 kB)
  • 145
    Antimicrobials are Associated with Adverse Cardiac Events Post AMI
    Linnea Polgreen, PhD ; Benjamin Riedle, MS ; Joseph Cavanaugh, PhD ; Mary Schroeder, PhD ; Philip M. Polgreen, MD

    CME Credits:

    ACPE Credits:

    ACPE Number:


    Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 7th with the exception of research findings presented at the IDWeek press conferences.